*Sponsored

(NYSE American: SER) Goes Green At The Bell As Key Chart Support Levels May Be Strengthening

October 8th

Dear Reader,

Serina Therapeutics, Inc. (NYSE: SER) has gone green quickly Wednesday AM and currently sits atop my watchlist.

Additionally, SER could be seeing potential support grow at three key chart levels:

• 50-Day Simple Moving Average (SMA)
• 200-Day SMA
• 13-Day Exponential Moving Average (EMA)

If support starts growing at those levels, it could act as the building blocks to continue a recent bullish trend that has seen SER climb from a $4.50 low just under 3 weeks ago.

Don’t forget. SER is a low float idea with just over 3Mn shares. That means volatility potential could be significantly heightened daily.

Take a moment to review my initial (NYSE: SER) report below and consider this profile for your watchlist.

—–

A little-known biopharma company is beginning to stand out.

Operating on the NYSE American, it’s developing innovative treatments for tough neurological conditions—though few seem to have noticed just yet.

That likely won’t last forever…

Its pipeline includes next-generation molecules, designed to target a range of central nervous system disorders and beyond.

Working closely with specialized collaborators, the company is also delving into RNA-based medicines for vaccine immunology, cancer immunotherapy, and gene therapy.

Its bold strategy reflects a clear mission: expanding what’s possible in modern medicine.

Mix in a low float of just over 3Mn shares (meaning volatility potential could be high), a couple of significant analyst targets, and recent PR highlights suggesting a company making transformative moves, and there’s little doubt why this biopharma idea has hit my radar.

Take a moment to consider pulling up this NYSE American idea:

Serina Therapeutics, Inc. (NYSE: SER)

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications.

Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs).

And based on several potential catalysts, (NYSE: SER) has my immediate attention and top watchlist spot. Take a look:

#1. A Low Float Could Create An Environment For Heightened Volatility.

#2. FDA Endorsement Accelerates Serina’s SER-252 Parkinson’s Treatment Pathway Progress.

#3. Serina Progresses Weekly Injectable Innovation For Tardive Dyskinesia Patients.

#4. Strategic Financing Empowers Serina’s Progress Toward Parkinson’s Breakthrough Therapy Approval.

#5. Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels.

But more on those in a second…

A Next-Gen Polymer Therapeutic

Serina Therapeutics’ proprietary POZ platform is built on a synthetic, water-soluble, low-viscosity polymer known as poly (2-oxazoline).

During the synthesis process, a precise amount of drug is incorporated onto the polymer backbone using pendant alkyne groups and metal-catalyzed “click chemistry.”

This POZ technology enables enhanced control over drug loading and allows for more precise management of drug release rates.

As a result, drugs with narrow therapeutic windows can be engineered to maintain more desirable and stable blood concentrations.

While optimized for small molecules, the platform is also applicable to proteins, aptamers, and other classes of molecules.

POZ Delivers Key Advantages

POZ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.

Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously.

They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure.

They have to be monitored and dose adjusted with greater frequency, and on an individual basis.

These fluctuations present clinical, compliance and quality of life challenges for many patients.

Administered Subcutaneously, POZ Provides Extended Delivery

Enabled by POZ

Serina Therapeutics is developing proprietary drugs to treat neurological diseases.

Its lead product candidate, SER-252 for advanced Parkinson’s disease, is expected to enter clinical trials in 2025.

Current discovery and development efforts include a focus on unlocking the potential of molecules across a range of CNS indications and beyond.

The company’s POZ platform partners are at the forefront of advancing novel RNA medicines in vaccine immunology, cancer immunotherapy, and gene therapy.

—–

(NYSE: SER) – These 5 Potential Catalysts Have Gained Our Attention!

#1. SER Potential Catalyst – A Low Float Could Create An Environment For Heightened Volatility.

According to info from the Yahoo Finance website, SER has a fairly low float.

The website reports this profile to have roughly 3.08Mn shares in its float.

Why is that important? It’s important on one crucial level. Volatility potential.

—–

#2. SER Potential Catalyst – FDA Endorsement Accelerates Serina’s SER-252 Parkinson’s Treatment Pathway Progress.

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway

 U.S. IND filing planned for Q4 2025 with U.S. enrollment expected to start in Q1 2026

– Patient dosing expected to begin in Australia in Q4 2025

HUNTSVILLE, AL, Aug. 25, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), …, today announced that following a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA’s written feedback supports advancing SER-252 (POZ-apomorphine) in a registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway.

“People living with advanced Parkinson’s need more consistent relief from motor fluctuations and our data to date suggest that SER-252 may reliably improve daily function,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “Based on the FDA’s written feedback, we plan to advance SER-252 on a registration-directed 505(b)(2) NDA regulatory pathway. Our development plan is designed to be rigorous and capital efficient. We aim to streamline a potential NDA while generating the clinical and pharmacologic evidence to support regulatory review and improve patients’ lives.”

In its discussions with the FDA, Serina outlined a program designed to leverage prior knowledge of apomorphine utilizing the company’s POZ-enabled profile. Serina plans to include a pharmacokinetic (PK) bridging component to an approved apomorphine product, consistent with a 505(b)(2) NDA strategy. The FDA’s feedback indicates that Serina’s initial study may be designed and conducted as a component of a registrational trial program, subject to standard clinical and nonclinical requirements and finalization of documentation at the time of IND submission.

“Beyond SER-252, we are advancing a pipeline of POZ-enabled small molecules that may follow similar 505(b)(2) NDA pathways where appropriate,” said Mr. Ledger. “The FDA’s feedback provides early proof-of-principle for our platform, confirming that we can effectively align with the agency’s expectations for the 505(b)(2) NDA regulatory pathway. Each program will follow its own science and require FDA dialogue, but our goal remains to unlock new possibilities in treatment and deliver better options to patients as quickly as possible.”

…

Read the full article here.

—–

#3. SER Potential Catalyst – Serina Progresses Weekly Injectable Innovation For Tardive Dyskinesia Patients.

Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

– Novel once-weekly injectable VMAT2 inhibitor targets underserved patients with serious adherence and access challenges –

– Potential expansion into Huntington’s chorea – an underserved indication with high need for long-acting VMAT2 therapy –

HUNTSVILLE, AL, July 29, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), …, today announced the advancement of its novel product candidate, SER-270, a proprietary POZ-conjugated vesicular monoamine transporter 2 (VMAT2) inhibitor in development for the treatment of tardive dyskinesia (TD).

SER-270, also referred to as POZ-VMAT2i, leverages Serina’s proprietary POZ polymer technology to enable long-acting, once weekly subcutaneous administration, offering a potentially transformative alternative to existing oral VMAT2 inhibitors. The candidate is designed to meet the needs of underserved TD patients who struggle with daily medication adherence, including those already managed with long-acting injectable (LAI) antipsychotics.

…

“POZ-VMAT2i embodies Serina’s commitment to solving real-world challenges for patients and caregivers who are often left behind by traditional therapies,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “By targeting non-compliant, institutionalized, and dysphagic patients with a transformative once-weekly injectable, we believe we can meaningfully expand access to proven VMAT2 inhibitor therapy and improve patient lives.”

Read the full article here.

—–

#4. SER Potential Catalyst – Strategic Financing Empowers Serina’s Progress Toward Parkinson’s Breakthrough Therapy Approval.

Serina Therapeutics Secures Up to $20Mn to Advance Registrational Trial of SER-252 in Parkinson’s Disease

Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkinson’s under the 505(b)(2) NDA pathway

Evaluating complementary funding including strategic equity and non-dilutive alternatives

HUNTSVILLE, AL, Sept. 09, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), …, today announced that it has entered into an agreement to access up to $20Mn in financing led by Serina Board Director Greg Bailey, MD. The financing also includes the issuance of warrants which, if fully issued and exercised, could result in additional proceeds of up to $20Mn.

“This financing provides the resources to advance SER-252 through critical clinical milestones on the path toward registration,” said Steve Ledger, Chief Executive Officer of Serina Therapeutics. “Importantly, the structure allows us to deploy capital in step with trial progress, while maintaining flexibility to access additional non-dilutive and strategic funding. We believe SER-252 has the potential to transform treatment for those with advanced Parkinson’s disease.”

…

Read the full article here.

—–

#5. SER Potential Catalyst – Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels.

TipRanks is sharing at least two analyst targets for SER:

Could SER be undervalued from current chart levels?

—–

The (NYSE: SER) Recap – 5 Potential Catalysts Lead The Way

#1. A Low Float Could Create An Environment For Heightened Volatility.

#2. FDA Endorsement Accelerates Serina’s SER-252 Parkinson’s Treatment Pathway Progress.

#3. Serina Progresses Weekly Injectable Innovation For Tardive Dyskinesia Patients.

#4. Strategic Financing Empowers Serina’s Progress Toward Parkinson’s Breakthrough Therapy Approval.

#5. Two Analyst Targets Imply That SER May Be Significantly Undervalued From Current Chart Levels.

—–

Coverage is officially reinitiated on Serina Therapeutics, Inc. (NYSE American: SER).

Updates will be coming soon. Keep your eyes peeled.

Sincerely,

FierceAnalyst | Jaks Swift

Editorial Writer

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)

*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor (“FI”) is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.

Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 10/07/2025 and ending on 10/08/2025 to publicly disseminate information about (SER:US) via digital communications. Under this agreement, SWN Media LLC has been paid seventeen thousand five hundred USD (“Funds”). To date, including under the previously described agreement, SWN Media LLC has been paid thirty five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither SWN Media LLC, TD Media LLC and their member own shares of (SER:US).

Please see important disclosure information here: https://fierceinvestor.com/disclosure/ser-jfla2/#details